RxDoctor Payments Data

Linda Gerrits, MD

Internal Medicine · Westlake Village, CANPI 1598875072

Payments from drug & device makers

$2,797in general payments, 2019–2025

Across 55 payments — averaging $50.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$497
  • Johnson & Johnson$350
  • Bayer$324
  • AbbVie$304
  • Astellas Pharma US Inc$269
  • AstraZeneca$217
  • plus $838 from 6 others

What the payments were for

  • Food & beverage$2,68896%
  • Education$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen10$497
Johnson & Johnson(2 entities)3$350
Bayer7$324
AbbVie(2 entities)4$304
Astellas Pharma US Inc9$269
AstraZeneca3$217
Lilly USA, LLC5$197
Novo Nordisk4$149
GSK4$141
Amarin Pharma, Inc.2$134
Therapeuticsmd, Inc.3$132
Vertiflex, Inc.1$84

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,797 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$69,143
Medicare patients
99
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$62,112
TrulicityDulaglutide14$29,857
FarxigaDapagliflozin Propanediol15$22,836
EliquisApixaban20$13,529
MyrbetriqMirabegron14$6,450
Breo ElliptaFluticasone/Vilanterol11$5,708
Olmesartan Medoxomil17$1,968
Escitalopram Oxalate77$1,230
Atorvastatin Calcium98$949
Levothyroxine Sodium76$815
Metoprolol Succinate33$751
Wixela InhubFluticasone Propion/Salmeterol11$617
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$567
Meloxicam31$470
Losartan Potassium46$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$62,11253 claims
Lilly USA, LLCTrulicity$197$29,85714 claims
AstraZenecaFarxiga$217$22,83615 claims
Astellas Pharma US IncMyrbetriq$269$6,45014 claims
GSKBreo Ellipta$141$5,70811 claims
AbbVieSynthroid$304$33211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westlake Village

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →